| Autor: |
Silvia Sánchez-Ramón, Lidia Fernández-Paredes, Paula Saz-Leal, Carmen M. Diez-Rivero, Juliana Ochoa-Grullón, Concepción Morado, Pilar Macarrón, Cristina Martínez, Virginia Villaverde, Antonia Rodríguez de la Peña, Laura Conejero, Keyla Hernández-Llano, Gustavo Cordero, Miguel Fernández-Arquero, Benjamin Fernández- Gutierrez, Gloria Candelas |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Frontiers in Immunology, Vol 12 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1664-3224 |
| DOI: |
10.3389/fimmu.2021.675735 |
| Popis: |
IntroductionConventional or biologic disease-modifying anti-rheumatic drugs (DMARDs) are the mainstay of treatment for systemic autoimmune disease (SAD). Infectious complications are a major concern in their use.ObjectiveTo evaluate the clinical benefit of sublingual mucosal polybacterial vaccines (MV130 and MV140), used to prevent recurrent respiratory and urinary tract infections, in patients with SAD and secondary recurrent infections following conventional or biologic DMARDs.MethodsAn observational study in SAD patients with recurrent respiratory tract infections (RRTI) and/or recurrent urinary tract infections (RUTI) was carried out. All patients underwent mucosal (sublingual) vaccination with MV130 for RRTI or with MV140 for RUTI daily for 3 months. Clinical evaluation was assessed during 12 months of follow-up after the first dose, i.e., 3 months under treatment and 9 months once discontinued, and compared with the previous year.ResultsForty-one out of 55 patients completed 1-year follow-up. All patients were on either conventional or biologic DMARDs. A significant decrease in the frequency of RUTI (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
